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S U M M A R Y
We report the case of a young female lung transplant recipient with difﬁcult-to-treat cytomegalovirus
(CMV) disease. While treatment with intravenous (IV) ganciclovir failed due to antiviral drug resistance,
a trial with foscarnet resulted in severe side effects. In addition, the patient received IV CMV-speciﬁc
immune globulins as adjunctive therapy and leﬂunomide as experimental therapy. In this context, CMV-
speciﬁc immune monitoring was performed and was successfully implemented in management
decisions. The patient was screened for acquisition of an adaptive immune response, and antiviral
prophylaxis and therapy was tailored according to results. This report highlights the impact of CMV-
speciﬁc immune monitoring on individualized therapy for appropriate prophylaxis and management of
CMV infection and diseases.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Cytomegalovirus (CMV) is the most prevalent opportunistic
infection that occurs in lung-transplant recipients. The most
important risk factor is CMV serological status, with D+/R- recipients
having the highest risk. CMV infection may evolve to CMV disease
with life threatening tissue invasive disease. CMV-induced immu-
nosuppression may lead to infection with other opportunistic
organisms and CMV infections have been associated with acute and
chronic rejection.1 CMV-speciﬁc immune monitoring may help to
identify the time point of acquisition of adaptive immune response
and therefore to tailor antiviral prophylaxis and therapy.
2. Case report
We report the case of a 42-year-old female solid organ
transplant recipient who underwent a double lung transplantation* Corresponding author. Tel.: +49 89 7095 3071; fax: +49 89 7095 8877.
E-mail address: nikolaus.kneidinger@med.uni-muenchen.de (N. Kneidinger).
http://dx.doi.org/10.1016/j.ijid.2014.06.009
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).for cystic ﬁbrosis. The recipient was CMV-seronegative and
received a graft from a CMV-seropositive donor.
The initial postoperative course was free of adverse events. The
recipient received a center-speciﬁc immunosuppressive regimen
with tacrolimus, mycophenolate mofetil (MMF), and prednisolone.
As preemptive therapy of CMV infection is part of routine care in
our center, the patient did not receive antiviral prophylaxis with
valganciclovir. Patients are monitored weekly for CMV infection
and treatment can be initiated immediately.
Shortly before hospital discharge, CMV PCR was positive for the
ﬁrst time (206 copies/ml). On the day of discharge, CMV DNA had
increased to 4300 copies/ml and treatment was initiated.
Treatment with valganciclovir 900 mg twice daily was started
and MMF was discontinued. The CMV viral load was successfully
decreased over the course of 4 weeks of rehabilitation (Figure 1).
No symptoms of CMV disease had occurred this far.
Upon routine visit to our outpatient clinic 2 months after
transplantation, CMV DNA was <150 copies/ml. CMV-speciﬁc
immunity was assessed using two commercially available ELISA
interferon gamma release assays (IGRAs) predicting CMV-speciﬁc
T-cell responses and by ﬂow cytometry analysis, investigating the
number of interferon gamma (IFN-g)-producing T-cells. All threeciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 1. Course of CMV burden and therapeutic interventions. VGCV-T, valganciclovir at a therapeutic dose of 900 mg twice daily; VGCV-P, valganciclovir at a prophylactic
dose of 450 mg twice daily; GCV, intravenous ganciclovir 5 mg/kg body weight twice daily; FOS, foscarnet (60 mg/kg body weight three times daily); IVIG, intravenous CMV-
speciﬁc immune globulin (Cytotect 100 international units (IU)/kg body weight); IM, immune monitoring.
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cy (f) of IFN-g-producing T-cells per 10 000 T-cells: Df CD8+/Df
CD4+ 6.6/1.8). Valganciclovir was continued at a prophylactic dose
of 450 mg twice daily and CMV DNA remained low at <150 copies/
ml over the following month.
However, 3 months after transplantation, the viral load
increased to 2820 copies/ml and the patient was admitted to
our center for further management. The patient reported signs of a
viral syndrome for the ﬁrst time, with malaise, fatigue, and
shivering. The patient was treated with intravenous (IV) ganciclo-
vir (5 mg/kg body weight twice daily) and IV CMV-speciﬁc immune
globulins. No evidence of tissue invasive diseases was found.
However, in the following days, her viral load increased further
to a maximum of 8050 copies/ml. Hence, testing for resistance
mutations was performed and treatment was switched to
foscarnet (60 mg/kg body weight three times daily), followed by
a second course of CMV-speciﬁc immune globulins. Ganciclovir
resistance was conﬁrmed by sequencing. A point mutation in the
UL97-kinase gene resulted in amino acid switch in codon 460 from
methionine to valine.
The viral load was reduced to 156 copies/ml within 2 weeks of
treatment escalation. However, the patient developed side effects
of antiviral treatment, with hypokalemia, hypomagnesaemia, and
impaired renal function. Weight gain due to generalized edema,
loss of appetite, nausea, and fever occurred. Due to the severity of
drug-related side effects, foscarnet was withdrawn. Consequently,
symptoms and electrolyte disturbances disappeared and kidney
function recovered.
Again, approximately 4 months after transplantation, CMV-
speciﬁc immunity was reassessed without signs of immunity. The
results of the assays were negative and the number of CMV-speciﬁc
T-cells (Df CD8+/Df CD4+ 9.7/6.4) remained low. Due to the lack of
immunity, another increase in CMV DNA was anticipated and a
therapeutic attempt with leﬂunomide was initiated. The patient
gave informed consent and received a loading dose of 100 mg
leﬂunomide, followed by 40 mg daily. Side effects of leﬂunomide
such as liver damage or myelosuppression did not occur.
Initially, CMV PCR remained low and the patient was
discharged. However, shortly after discontinuing foscarnet and
starting leﬂunomide, CMV DNA started to increase again over the
following weeks (maximum 2470 copies/ml). In agreement with
the patient, we did not initiate antiviral therapy with foscarnet
again. Due to nephrotoxicity, cidofovir was not an option in this
case. However, a modiﬁcation of the immunosuppressive regimen
was discussed.
In the following days (approximately 5 months after transplan-
tation), the CMV viral load started to decrease and CMV-speciﬁcimmunity was assessed once more. For the ﬁrst time, the patient
demonstrated an appropriate immune response and the presence
of CMV-speciﬁc T-cells (Df CD8+/Df CD4+ 36.8/46.8). Serological
testing revealed positive CMV IgG and IgM levels, indicating the
early stages of B-cell-mediated immunity.
Our patient remained on calcineurin inhibitor (CNI)-based
immunosuppression, and MMF was exchanged for azathioprine.
Leﬂunomide was maintained as adjunctive therapy.
More than 1 year later, the patient remains healthy without any
signs of CMV infection.
3. Discussion
We report a lung transplant recipient with difﬁcult-to-treat
CMV disease and focus on the impact of detailed knowledge of
immune status for appropriate management. In the context of
ganciclovir resistance, side effects of second-line antiviral drugs,
and experimental therapies, the need for CMV-speciﬁc immune
monitoring is highlighted.
Despite receiving a prophylactic dose of valganciclovir followed
by a full dose of IV ganciclovir over 1 week, the patient exhibited an
increase in viral load, highly suggestive of antiviral drug resistance.
Knowledge of resistance mutations is essential for further
treatment. Depending on the type of mutation, different levels
of antiviral drug resistance must be expected.1 Foscarnet is the
treatment of choice in the case of ganciclovir resistance, but side
effects are frequent and may limit its clinical use, as reported in our
case.
CMV-speciﬁc immune monitoring may help to identify the time
point of acquisition of an adaptive immune response and therefore
to tailor antiviral prophylaxis and therapy. The value of immunity
testing has not been assessed in randomized clinical trials and is
not yet applied in clinical routine. Two assays were used in this
case. Whereas the QuantiFERON-CMV (Cellestis) assay is used to
detect IFN-g secreted by CD8+ T-cells, the T-Track CMV (Lophius
Biosciences) allows quantiﬁcation of IFN-g-secreting CD4+ and
CD8+ T-cells after speciﬁc stimulation. Furthermore, ﬂow cyto-
metry provides quantitative and qualitative characteristics of
CMV-speciﬁc T-cells. The above mentioned methods have been
suggested to be predictive of CMV disease.2 Moreover, antibody
measurements were performed in our patient. Whereas, CMV IgG
levels may be inﬂuenced by the administration of IV CMV-speciﬁc
immune globulins, CMV IgM may indicate early humoral
immunity. CMV serology testing has no impact on the manage-
ment of CMV infection. However, lack of seroconversion may be
useful for the identiﬁcation of patients at risk of late-onset CMV
disease.3
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sive and anti-CMV activity.4 The mechanism of action conferring
the antiviral activity remains unknown. In vitro phenotypic assays
have indicated that leﬂunomide is active against both wild-type
and ganciclovir-resistant CMV strains,4 and leﬂunomide has been
used to treat CMV in a few patients.5
In our patient, CMV PCR remained low for 2 weeks after the
introduction of leﬂunomide, but then went up again over the next
2 weeks. The following and ﬁnal decrease in CMV DNA correlated
well with the concurrent development of a CMV-speciﬁc immune
response. Therefore, the reasons for disease control might have
been two-fold: the antiviral effect of leﬂunomide and/or the
development of CMV-speciﬁc immunity. A CMV-speciﬁc immune-
modulatory effect by leﬂunomide has not been reported so far.
In the context of antiviral treatment failure, alternative
strategies were discussed. Previous studies have shown that
regimens based on mTOR inhibitors might reduce CMV infections.
Since our patient demonstrated immunity, she remained on a CNI-
based immunosuppressive regimen and remained healthy without
signs of CMV infection.
In conclusion, antiviral drug-resistant CMV disease is a rare but
important threat. Detailed knowledge of the resistance proﬁle is
crucial to guide treatment. Furthermore, the presented casehighlights the impact of immune monitoring in affected individu-
als and raises awareness of the need for a more sophisticated,
individualized approach to prevent CMV infections, beyond
standard prophylaxis or preemptive therapy. Measures of CMV-
speciﬁc immunity might help to guide treatment and assess
experimental drugs in vivo.
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